RU95112241A - METHOD FOR CORRECTION OF SIDE EFFECTS OF CHEMICAL RADIATION THERAPY - Google Patents

METHOD FOR CORRECTION OF SIDE EFFECTS OF CHEMICAL RADIATION THERAPY

Info

Publication number
RU95112241A
RU95112241A RU95112241/14A RU95112241A RU95112241A RU 95112241 A RU95112241 A RU 95112241A RU 95112241/14 A RU95112241/14 A RU 95112241/14A RU 95112241 A RU95112241 A RU 95112241A RU 95112241 A RU95112241 A RU 95112241A
Authority
RU
Russia
Prior art keywords
side effects
correction
radiation therapy
chemical radiation
administration
Prior art date
Application number
RU95112241/14A
Other languages
Russian (ru)
Other versions
RU2110995C1 (en
Inventor
А.В. Асафов
В.В. Безюлев
Е.И. Нестерова
М.Б. Бычков
В.А. Горбунова
И.Д. Трещалин
Д.А. Бодягин
Э.Р. Переверзева
Э.К. Возный
Д.Б. Корман
В.И. Борисов
Е.М. Трещалина
Original Assignee
Научно-производственное предприятие "Фармэк"
Filing date
Publication date
Application filed by Научно-производственное предприятие "Фармэк" filed Critical Научно-производственное предприятие "Фармэк"
Priority to RU95112241/14A priority Critical patent/RU2110995C1/en
Priority claimed from RU95112241/14A external-priority patent/RU2110995C1/en
Publication of RU95112241A publication Critical patent/RU95112241A/en
Application granted granted Critical
Publication of RU2110995C1 publication Critical patent/RU2110995C1/en

Links

Claims (3)

1. Способ коррекции побочных эффектов химиолучевой терапии, включающий введение производных нуклеиновых кислот, отличающийся тем, что используют натрия нуклеоспермат в дозах 15 - 225 мг, причем перед введением препарат нагревают, а введение осуществляют подкожно, медленно.1. A method for correcting side effects of chemoradiotherapy, including the introduction of nucleic acid derivatives, characterized in that sodium nucleospermate is used in doses of 15-225 mg, the preparation is heated before administration and the administration is carried out subcutaneously, slowly. 2. Способ по п.1, отличающийся тем, что при острой лейкопении препарат вводят с второго дня применения цитостатиков по схеме САМ в течение 1 - 10 дней. 2. The method according to claim 1, characterized in that in acute leukopenia, the drug is administered from the second day of the use of cytostatics according to the CAM scheme for 1 to 10 days. 3. Способ по п. 2, отличающийся тем, что при хронической лейкопении введение осуществляют после курса проведения химиотерапии, однократно или в течение 3 - 8 дней. 3. The method according to p. 2, characterized in that in chronic leukopenia, administration is carried out after a course of chemotherapy, once or within 3 to 8 days.
RU95112241/14A 1995-07-17 1995-07-17 Method of correction of adverse effects of chemistry-radiation therapy RU2110995C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU95112241/14A RU2110995C1 (en) 1995-07-17 1995-07-17 Method of correction of adverse effects of chemistry-radiation therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU95112241/14A RU2110995C1 (en) 1995-07-17 1995-07-17 Method of correction of adverse effects of chemistry-radiation therapy

Publications (2)

Publication Number Publication Date
RU95112241A true RU95112241A (en) 1997-07-10
RU2110995C1 RU2110995C1 (en) 1998-05-20

Family

ID=20170172

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95112241/14A RU2110995C1 (en) 1995-07-17 1995-07-17 Method of correction of adverse effects of chemistry-radiation therapy

Country Status (1)

Country Link
RU (1) RU2110995C1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2206326C2 (en) * 2001-04-10 2003-06-20 Асафов Александр Виленович Application of sodium nucleospermate for treatment of hiv-infection and method of treatment

Similar Documents

Publication Publication Date Title
HUT38263A (en) Process for rendering active substances soluble and production of therapeutic compositions comprising these substances
ATE101340T1 (en) NEW DRUG FORMULATION AND METHOD OF PRODUCTION.
FI945621A (en) Controlled solvents
DK542279A (en) PHARMACEUTICAL PREPARATION CONTAINING A HEALTH-CONTROLLING GLYCOSIDE WITH A POLYMER COATING
KR910019618A (en) Pharmaceutical composition for treating erectile dysfunction
DK1039900T3 (en) Pharmaceutical preparation containing sibutramine and orlistat
AU6788687A (en) A pharmaceutical which can be administered nasally, a process for its preparation, and its use
Eberl et al. Meclofenamate sodium in the treatment of acute gout. Results of a double-blind study
ATE55248T1 (en) DRUG COMBINATION.
RU95112241A (en) METHOD FOR CORRECTION OF SIDE EFFECTS OF CHEMICAL RADIATION THERAPY
EP0271151A3 (en) Azumolene dosage form
PT891186E (en) Nasal administration of agents for treatment of delayed onset emesis
Jonsson Development of long-acting nitrate delivery systems
RU94013606A (en) Hemostimulator
RU97112236A (en) METHOD FOR TREATING MALIGNANT BONE TUMORS AND METASTASES IN OSTEOLITICAL CHARACTER BONE
RU94036344A (en) Method for treating aids cases
RU96103669A (en) METHOD FOR TREATING SARCOIDOSIS
RU97110383A (en) METHOD FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS
RU96122672A (en) ECHINAMAX. METHOD OF TREATMENT OF ASTHENIC CONDITIONS IN PHYSIOGENIC DISADAPTATIONS
IT8323253A0 (en) PREPARATION FOR THE TREATMENT OF WITHDRAWAL CRISIS IN DRUG ADDICTS.
IE38235B1 (en) Preparations for combatting swine dysentery
RO92640B1 (en) Method for treating viral keratoiditis
RU99112967A (en) METHOD FOR TREATMENT AND PREVENTION OF PIG DYSENTERY
RU92013625A (en) DRUGS, STIMULATING ERYTHROID GROWTH BLOOD DURING CYTOSTATIC MYELOPRESSIONS
RU94023600A (en) METHOD FOR TREATING HEMOCHROMATOSIS